Company · GSK
GSK
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
148
57 still marketed
Novel approvals
49
Approvals since 2021
66
Originals and new uses
Phase 3 trials
949
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Hibsago approved NovelPriority reviewOct 20, 2026
- Jemperli new use Priority reviewOct 19, 2026
- Tivicay new use Priority reviewAug 25, 2026
- Tivicay Pd new use Priority reviewAug 25, 2026
- Utebzi approved NovelPriority reviewJun 17, 2026
- Wellcovorin new use Priority reviewMar 9, 2026
- Exdensur approved NovelDec 16, 2025
- Blujepa new use Priority reviewDec 11, 2025
- Blenrep approved OrphanOct 23, 2025
- Benlysta new use Jun 20, 2025
Drugs in development (61)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- EfimosferminBOS-580Phase 37 trials
GSK · Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic
- GlucocorticoidsPhase 37 trials
Novartis · VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease
- Mocertatug rezetecanMo-RezPhase 36 trials
GSK · Ovarian Neoplasms, Neoplasms, Endometrial, Tumours, Gynecological
- rHuPH20Phase 35 trials
Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma
- CamlipixantBLU-5937Phase 34 trials
GSK · Refractory Chronic Cough, Cough, Irritable Bowel Syndrome
- CAPEOXPhase 34 trials
GSK · Neoplasms, Colon, Colonic Neoplasms, Colorectal Adenoma
- DTap-HepB-IPV-Hib vaccineHexyon, Infanrix hexaPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunization, Pneumococcal Immunization
- BelrestotugEOS884448, GSK4428859APhase 33 trials
GSK · Lung Cancer, Non-Small Cell, Neoplasms, Head and Neck
- Marketed varicella vaccinePhase 33 trials
GSK · Chickenpox
- MMR vaccinePhase 33 trials
GSK · Chickenpox
- RSVPreF3 OA investigational vaccinePhase 33 trials
GSK · Respiratory Syncytial Virus Infections
- VelzatinibGSK6042981Phase 33 trials
GSK · Gastrointestinal Neoplasms, Gastrointestinal Stromal Neoplasms
- 2 NRTIsPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections
- ABC3TC STR, 3TC immediate releasePhase 32 trials
GSK · HIV Infections
- ARTPhase 32 trials
GSK · HIV Infections, HIV-1 Infection
- CobolimabPhase 32 trials
GSK · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma
- DTGPhase 32 trials
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus, HIV Infections
- HFA-134aPhase 32 trials
GSK · Asthma
- HFA-152aPhase 32 trials
GSK · Asthma
- Investigational varicella vaccinePhase 32 trials
GSK · Chickenpox
- RSVPreF3 OA vaccinePhase 32 trials
GSK · Respiratory Syncytial Virus Infections
Recruiting Phase 3 trials
Largest first.
- A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of AgePivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07851246 · 3,000 participants (planned) · Start Oct 1, 2026 · Primary completion Jul 9, 2027
Drug: mRNA Seasonal Flu vaccine; Comparator 1 and 1 more · For: Influenza, Human
Sites: Glendale, Arizona; Tucson, Arizona; San Diego, California · 12 sites in all
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of AgePivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT06740630 · 1,840 participants (planned) · Start Jan 10, 2025 · Primary completion Dec 25, 2026
Drug: Investigational varicella vaccine_Lot 1; Investigational varicella vaccine_Lot 2 and 8 more · For: Chickenpox
Sites: Mobile, Alabama; Hot Springs, Arkansas; Sherwood, Arkansas · 97 sites in all
- A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07701993 · 1,740 participants (planned) · Start Jul 22, 2026 · Primary completion Jun 23, 2033
Drug: Efimosfermin alfa; Placebo · For: Metabolic Dysfunction-associated Steatohepatitis
Sites: Little Rock, Arkansas; Folsom, California; Montclair, California · 37 sites in all
- A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASHPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07221188 · 1,250 participants (planned) · Start Dec 12, 2025 · Primary completion Mar 24, 2028
Drug: Efimosfermin Alfa; Placebo · For: Non-alcoholic Fatty Liver Disease
Sites: Arcadia, California; Covina, California; Los Angeles, California · 66 sites in all
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of AgePivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07406360 · 1,209 participants (planned) · Start May 11, 2026 · Primary completion Feb 28, 2028
Drug: MMRVNS; MMRV · For: Measles; Measles-Mumps-Rubella+Chickenpox Vaccine
Sites: Birmingham, Alabama; Walnut Creek, California; Miami, Florida · 17 sites in all
- A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASHPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07221227 · 1,200 participants (planned) · Start Oct 24, 2025 · Primary completion Mar 29, 2028
Drug: Efimosfermin alfa; Efimosfermin alfa and 1 more · For: Non-alcoholic Fatty Liver Disease
Sites: Chandler, Arizona; Tucson, Arizona; Little Rock, Arkansas · 91 sites in all
- eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07177339 · 1,196 participants (planned) · Start Oct 20, 2025 · Primary completion Apr 2, 2029
Drug: Depemokimab; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Sheffield, Alabama; Tucson, Arizona; Escondido, California · 293 sites in all
- Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 InflammationPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT06959095 · 981 participants (planned) · Start Jun 20, 2025 · Primary completion Dec 13, 2028
Drug: Depemokimab; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Bakersfield, California; Modesto, California; Newport Beach, California · 281 sites in all
- Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT06961214 · 961 participants (planned) · Start Jun 23, 2025 · Primary completion Dec 13, 2028
Drug: Depemokimab; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Sheffield, Alabama; Aurora, Colorado; Brooksville, Florida · 193 sites in all
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of AgePivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT06855160 · 911 participants (planned) · Start Apr 17, 2025 · Primary completion Sep 10, 2026
Drug: Candidate varicella vaccine; Marketed varicella vaccine and 5 more · For: Chickenpox
Sites: Tucson, Arizona; Huntington Park, California; Sherman Oaks, California · 22 sites in all
Marketed drugs (57)
Newest FDA action first.
- Benlysta Belimumab · 2017
- Hibsago Bepirovirsen Sodium · 2026
- Jemperli Dostarlimab-Gxly · 2021
- Tivicay Dolutegravir Sodium · 2013
- Tivicay Pd Dolutegravir Sodium · 2020
- Brexafemme Ibrexafungerp Citrate · 2021
- Ojjaara Momelotinib Dihydrochloride · 2023
- Utebzi Tebipenem Pivoxil Hydrobromide · 2026
- Exdensur Depemokimab-Ulaa · 2025
- Malarone Pediatric Atovaquone, Proguanil Hydrochloride · 2000
- Zejula Niraparib Tosylate · 2023
- Mepron Atovaquone · 1995
- Blujepa Gepotidacin Mesylate · 2025
- Imitrex Statdose (Autoinjector) Sumatriptan Succinate · 1992
- Imitrex Sumatriptan · 1997
- Imitrex Sumatriptan Succinate · 1995
- Cabenuva Kit Cabotegravir, Rilpivirine · 2021
- Valtrex Valacyclovir Hydrochloride · 1995
- Wellbutrin Sr Bupropion Hydrochloride · 1996
- Triumeq Abacavir Sulfate, Dolutegravir Sodium, Lamivudine · 2014
- Dovato Dolutegravir Sodium, Lamivudine · 2019
- Juluca Dolutegravir Sodium, Rilpivirine Hydrochloride · 2017
- Triumeq Pd Abacavir Sulfate, Dolutegravir Sodium, Lamivudine · 2022
- Blenrep Belantamab Mafodotin-Blmf · 2025
- Lamictal Xr Lamotrigine · 2009
- Lamictal Lamotrigine · 1994
- Lamictal Cd Lamotrigine · 1998
- Lamictal Odt Lamotrigine · 2009
- Nucala Mepolizumab · 2019
- Nucala Mepolizumab · 2015
- Apretude Cabotegravir · 2021
- Vocabria Cabotegravir Sodium · 2021
- Retrovir Zidovudine · 1987
- Retrovir Zidovudine · 1989
- Retrovir Zidovudine · 1990
- Rukobia Fostemsavir Tromethamine · 2020
- Incruse Ellipta Umeclidinium Bromide · 2014
- Relenza Zanamivir · 1999
- Arnuity Ellipta Fluticasone Furoate · 2014
- Anoro Ellipta Umeclidinium Bromide, Vilanterol Trifenatate · 2013
- Trelegy Ellipta Fluticasone Furoate, Umeclidinium Bromide, Vilanterol Trifenatate · 2017
- Breo Ellipta Fluticasone Furoate, Vilanterol Trifenatate · 2013
- Advair Hfa Fluticasone Propionate, Salmeterol Xinafoate · 2006
- Flovent Hfa Fluticasone Propionate · 2004
- Ventolin Hfa Albuterol Sulfate · 2001
- Jemperli Dostarlimab-Gxly · 2021
- Ziagen Abacavir Sulfate · 1998
- Krintafel Tafenoquine Succinate · 2018
- Selzentry Maraviroc · 2007
- Selzentry Maraviroc · 2016
- Serevent Salmeterol Xinafoate · 1997
- Epivir Lamivudine · 2004
- Epivir Lamivudine · 1995
- Flovent Diskus 250 Fluticasone Propionate · 2000
- Advair Diskus 500/50 Fluticasone Propionate, Salmeterol Xinafoate · 2000
- Lamictal Xr Lamotrigine · 2010
- Valtrex Valacyclovir Hydrochloride · 1995
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.